Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals.
- Resource Type
- Article
- Authors
- Beca, J.; Chan, K. K. W.
- Source
- Current Oncology. Aug2016, Vol. 23 Issue 4, pe327-e329. 3p.
- Subject
- *ANTINEOPLASTIC agents
*DRUG prices
*DRUG efficacy
*COST effectiveness
*RENAL cancer treatment
*METASTASIS
*CANCER treatment
*QUALITY of life
*MEDICAL care
- Language
- ISSN
- 1198-0052
The article focuses on a study regarding cost-effectiveness of pazopanib in comparison to sunitinib for treatment of metastatic renal cell carcinoma (mrcc) in Canada. Topics discussed include higher effectiveness of pazopanib, comparative analysis of the medicines on basis of the improvement of health-related quality of life, and access of patients to both the medicines.